Sequential versus continual purified urinary FSH/hCG in men with idiopathic hypogonadotropic hypogonadism

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 6, 2015, Pages 2449-2455

  Zhang, Manna ^a   Tong, Guoyu ^b   Liu, Yanling ^a   Mu, Yiming ^c   Weng, Jianping ^d   Xue, Yaoming ^e   Luo, Zuojie ^f   Xue, Yuanming ^g   Shi, Lixin ^h   Wu, Xueyan ⁱ   Sun, Shouyue ^a   Zhu, Yanhua ^d   Cao, Ying ^e   Zhang, Jie ^f   Huang, Hong ^b   Niu, Ben ^g   Li, Hong ^h   Guo, Qinghua ^c   Gao, Yan ^c   Li, Zhibin ^j   Ning, Guang ^a   Zhu, Dalong ^b   Li, Xiaoying ^a   more..

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d SUN YAT SEN UNIVERSITY   (China)

^e SOUTHERN MEDICAL UNIVERSITY   (China)

^f GUANGXI MEDICAL UNIVERSITY   (China)

^g Department of Infectious Diseases and Liver Diseases   (China)

^h GUIZHOU MEDICAL UNIVERSITY   (China)

ⁱ PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^j THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN; FOLLITROPIN; TESTOSTERONE; UROFOLLITROPIN;

ADULT; ARTICLE; CHINESE; CONTROLLED STUDY; COST CONTROL; DRUG COST; DRUG INTERMITTENT THERAPY; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PENIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SPERMATOGENESIS; SPERMATOZOON COUNT; SPERMATOZOON DENSITY; SPERMATOZOON MOTILITY; TESTIS SIZE; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; YOUNG ADULT; ADOLESCENT; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; FOLLOW UP; HYPOGONADISM; ISOLATION AND PURIFICATION; MIDDLE AGED; TESTIS; URINE;

ADOLESCENT; ADULT; CHORIONIC GONADOTROPIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; SPERM COUNT; SPERMATOGENESIS; TESTIS; UROFOLLITROPIN; YOUNG ADULT;

EID: 84930790944     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-3802     Document Type: Article

References (29)

1. Basaria S. Male hypogonadism. Lancet. 2014;383:1250-1263.
2. Balasubramanian R, Crowley WF Jr. Isolated GnRH deficiency: a disease model serving as a unique prism into the systems biology of the GnRH neuronal network. Mol Cell Endocrinol. 2011;346:4-12.
3. Bhagavath B, Podolsky RH, Ozata M, et al. Clinical and molecular characterization of a large sample of patients with hypogonadotropic hypogonadism. Fertil Steril. 2006;85:706-713.
4. Raivio T, Wikström AM, Dunkel L. Treatment of gonadotropin-deficient boys with recombinant human FSH: long-term observation and outcome. Eur J Endocrinol. 2007;156:105-111.
5. Delemarre-van de Waal HA. Application of gonadotropin releasing hormone in hypogonadotropic hypogonadism - diagnostic and therapeutic aspects. Eur J Endocrinol. 2004;151(suppl 3):U89-U94.
6. Christiansen P, Skakkebaek NE. Pulsatile gonadotropin-releasing hormone treatment of men with idiopathic hypogonadotropic hypogonadism. Horm Res. 2002;57:32-36.
7. Vicari E, Mongioì A, Calogero AE, et al. Therapy with human chorionic gonadotrophin alone induces spermatogenesis in men with isolated hypogonadotrophic hypogonadism - long-term follow-up. Int J Androl. 1992;15:320-329.
8. Kirk JM, Savage MO, Grant DB, Bouloux PM, Besser GM. Gonadal function and response to human chorionic and menopausal gonadotropin therapy in male patients with idiopathic hypogonadotrophic hypogonadism. Clin Endocrinol (Oxf). 1994;41:57-63.
9. Büchter D, Behre HM, Kliesch S, Nieschlag E. Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases. Eur J Endocrinol. 1998;139:298-303.
10. Liu L, Banks SM, Barnes KM, Sherins RJ. Two-year comparison of testicular responses to pulsatile gonadotropin-releasing hormone and exogenous gonadotropins from the inception of therapy in men with isolated hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 1988;67:1140-1145.
11. Han TS, Bouloux PM. What is the optimal therapy for young males with hypogonadotropic hypogonadism? Clin Endocrinol (Oxf). 2010;72:731-737.
12. Petak SM, Nankin HR, Spark RF, Swerdloff RS, Rodriguez-Rigau LJ, American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients - 2002 update. Endocr Pract. 2002;8:440-456.
13. Depenbusch M, von Eckardstein S, Simoni M, Nieschlag E. Maintenance of spermatogenesis in hypogonadotropic hypogonadal men with human chorionic gonadotropin alone. Eur J Endocrinol. 2002; 147:617-624.
14. Johnsen SG. Maintenance of spermatogenesis induced by HMG treatment by means of continuous HCG treatment in hypogonadotrophic men. Acta Endocrinol (Copenh). 1978;89:763-769.
15. Bouloux PM, Nieschlag E, Burger HG, et al. Induction of spermatogenesis by recombinant follicle-stimulating hormone (Puregon) in hypogonadotropic azoospermic men who failed to respond to human chorionic gonadotropin alone. J Androl. 2003;24:604-611.
16. Burgués S, Calderón MD. Subcutaneous self-administration of highly purified follicle stimulating hormone and human chorionic gonadotrophin for the treatment of male hypogonadotrophic hypogonadism. Spanish Collaborative Group on Male Hypogonadotropic Hypogonadism. Hum Reprod. 1997;12:980-986.
17. Ishikawa T, Ooba T, Kondo Y, Yamaguchi K, Fujisawa M. Assessment of gonadotropin therapy in male hypogonadotropic hypogonadism. Fertil Steril. 2007;88:1697-1699.
18. Sakamoto H, Saito K, Oohta M, Inoue K, Ogawa Y, Yoshida H. Testicular volume measurement: comparison of ultrasonography, orchidometry, and water displacement. Urology. 2007;69:152-157.
19. World Health Organization. WHO Laboratory Manual for the Examination and Processing of Human Semen. 5th ed. Geneva, Switzerland: World Health Organization; 2009.
20. Warne DW, Decosterd G, Okada H, Yano Y, Koide N, Howles CM. A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human follicle-stimulating hormone and human chorionic gonadotropin. Fertil Steril. 2009;92:594-604.
21. Dorothee B, Hermann M B, Sabine K, Eberhard N. Efficacy and safety of highly purified urinary follicle-stimulating hormone with human chorionic gonadotropin for treating men with isolated hypogonadotropic hypogonadism. European Metrodin HP Study Group. Fertil Steril. 1998;70:256-262.
22. Bouloux P, Warne DW, Loumaye E. Efficacy and safety of recombinant human follicle-stimulating hormone in men with isolated hypogonadotropic hypogonadism. Fertil Steril. 2002;77:270-273.
23. Barrio R, de Luis D, Alonso M, Lamas A, Moreno JC. Induction of puberty with human chorionic gonadotropin and follicle-stimulating hormone in adolescent males with hypogonadotropic hypogonadism. Fertil Steril. 1999;71:244-248.
24. Matsumoto AM, Snyder PJ, Bhasin S, et al. Stimulation of spermatogenesis with recombinant human follicle-stimulating hormone (follitropin alfa; GONAL-f): long-term treatment in azoospermic men with hypogonadotropic hypogonadism. Fertil Steril. 2009;92: 979-990.
25. Liu PY, Baker HW, Jayadev V, Zacharin M, Conway AJ, Handelsman DJ. Induction of spermatogenesis and fertility during gonadotropin treatment of gonadotropin-deficient infertile men: predictors of fertility outcome. J Clin Endocrinol Metab. 2009;94:801-808.
26. Kamischke A, Behre HM, Bergmann M, Simoni M, Schäfer T, Nieschlag E. Recombinant human follicle stimulating hormone for treatment of male idiopathic infertility: a randomized, double-blind, placebo-controlled, clinical trial. Hum Reprod. 1998;13:596-603.
27. Liu PY, Turner L, Rushford D, et al. Efficacy and safety of recombinant human follicle stimulating hormone (Gonal-F) with urinary human chorionic gonadotrophin for induction of spermatogenesis and fertility in gonadotrophin-deficient men. Hum Reprod. 1999; 14:1540-1545.
28. Hoomans EH, Andersen AN, Loft A, Leerentveld RA, van Kamp AA, Zech H. A prospective, randomized clinical trial comparing 150 IU recombinant follicle stimulating hormone (Puregon) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP) in a fixed-dose regimen in women undergoing ovarian stimulation. Hum Reprod. 1999;14:2442-2447.
29. Ogawa M, Yazawa T, Mori O. Men with pituitary dwarfism and gonadotropin deficiency successfully fathered children following HCG-HMG treatment. Clin Pediatr Endocrinol. 2000;9:89-96.